Cantargia AB: Cantargia reports first non-squamous NSCLC patient treated with nadunolimab, Keytruda and chemotherapy

LUND, Sweden, Sept. 22, 2022 /PRNewswire/ -- Cantargia (Cantargia AB) (Nasdaq: CANTA) (Stockholm: CANTA) today reported that the first patient has been treated in a new arm of the phase Ib clinical

Related Keywords

Sweden ,Stockholm ,Prnewswire Cantargia , ,Nasdaq Stockholm ,Cantargia ,Reports ,First ,Squamous ,Nsclc ,Patient ,Reated ,Adunolimab ,Keytruda ,Chemotherapy ,